Month: April 2022

Release – Allegiant Initiates Plan-of-Operations at Castle Area to Further Expand Permitted Area at Eastside

Posted on by Admin



Allegiant Initiates Plan-of-Operations at Castle Area to Further Expand Permitted Area at Eastside

Research, News, and Market Data on Allegiant Gold

Reno, Nevada /April 12, 2022 – Allegiant Gold Ltd. (“Allegiant”
or the “Company”) (AUAU: TSX-V) (AUXXF: OTCQX) is pleased to announce the commencement of a Plan-of-Operations at the Castle Area within their Flagship Eastside Project near Tonopah, Nevada expanding the potential permitted area to approximately 1,648 acres. 

The Castle Area is comprised of 130 claims encompassing an area of approximately 2,600 acres, and includes four deposits: Berg, Blackrock, Boss and Castle.  The Castle Area denotes the southernmost part of Allegiant’s Eastside Project and is contiguous to the other claims at Eastside.  In late 2020 and early 2021, Allegiant drilled 49 reverse circulation (“RC”) holes at the Castle Area for a total of 5,850 metres with the following highlights:

  • 47 holes encountered mineralization within 45m from surface;
  • Significant intercepts included:
    • 5m of 1.85 g/t Au from Hole ES-196
    • 14m of 1.08 g/t Au from Hole ES-202
    • 4.5m of 2.32 g/t Au from Hole ES-211
    • 3.6m of 2.00 g/t Au from Hole ES-216
    • 1.5m of 3.86 g/t Au from Hole ES-222

The Castle Area hosts an inferred resource of 314,000
gold ounces at 0.48 g/t within a pit-constrained model using a cut-off grade of 0.15 g/t gold, US$1,750/ounce gold price and a US$21.88 silver price.*

Peter Gianulis, CEO of
Allegiant Gold, commented: “The commencement of a Plan-of-Operations is an important next step in the development of the Castle Area at Eastside allowing us to dramatically increase drilling and technical work.  We have applied to expand the permitted area from 5 acres to over 1648 acres.  Our goal at the Castle Area in the next stage of exploration will be to expand the existing resource, upgrade a portion from Inferred to Measured and Indicated, as well as conduct more advanced metallurgical work in anticipation of an eventual preliminary economic assessment.”

*Eastside Resource Estimate
The updated resource estimate (“Updated Resource Estimate and NI 43-101 Technical Report, Eastside and Castle Gold-Silver Project Technical Report, Esmeralda County, Nevada”) was conducted by Mine Development Associates (“MDA”) of Reno, Nevada with an effective date of July 30, 2021.  Contained pit-constrained Inferred Resources (cut-off grade of 0.15 g/t) of 1,090,00 Au ounces at 61,730,000 tonnes at 0.55 g/t Au and 8,700,000 Ag ounces at 4.4 g/t Ag at the Original Pit Zone and 314,000 Au ounces at 19,986,000 tonnes at 0.49 g/t Au at the Castle Area. In accordance with NI 43-101 the MDA Technical Report dated July 30, 2021 is filed on SEDAR.  This report builds on and supersedes the NI 43-101 reports of Ristorcelli (December 2016), Ristorcelli (July 2017) and Ristorcelli (January 2020) titled “Resource
Estimate and Technical Report, Eastside Gold-Silver Project, Esmeralda County,
Nevada” prepared for Allegiant with an Effective Date of July 25, 2017. 

MAP 1: CASTLE AREA PERMIT AREA

QUALIFIED PERSON
Andy Wallace is a Certified Professional Geologist (CPG) with the American Institute of Professional Geologists and is the Qualified Person under NI 43-101, Standards of Disclosure for Mineral Projects, who has reviewed and approved the scientific and technical content of this press release. 



ABOUT ALLEGIANT
Allegiant owns 100% of 10 highly-prospective gold projects in the United States, seven of which are located in the mining-friendly jurisdiction of Nevada. Three of Allegiant’s projects are farmed-out, providing for cost reductions and cash-flow. Allegiant’s flagship, district-scale Eastside project hosts a large and expanding gold resource and is located in an area of excellent infrastructure. Preliminary metallurgical testing indicates that both oxide and sulphide gold mineralization at Eastside is amenable to heap leaching.



ON BEHALF OF THE BOARD
Peter Gianulis
CEO

 

For more information contact:
Investor Relations
(604) 634-0970 or
1-888-818-1364


ir@allegiantgold.com



Neither TSX Venture
Exchange nor its Regulation Services Provider (as that term is defined in
policies of the TSX Venture Exchange) accepts responsibility for the adequacy
or accuracy of this release.

Certain statements and information contained in
this press release constitute “forward-looking statements” within the
meaning of applicable U.S. securities laws and “forward-looking information”
within the meaning of applicable Canadian securities laws, which are referred
to collectively as “forward-looking statements”. The United States
Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for
certain forward-looking statements. Allegiant Gold Ltd.’s (“Allegiant”) exploration plans for its gold
exploration properties, the drill program at Allegiant’s Eastside project, the
preparation and publication of an updated resource estimate in respect of the
Original Zone at the Eastside project, Allegiant’s future exploration and
development plans, including anticipated costs and timing thereof; Allegiant’s
plans for growth through exploration activities, acquisitions or otherwise; and
expectations regarding future maintenance and capital expenditures, and working
capital requirements.  Forward-looking statements are statements and
information regarding possible events, conditions or results of operations that
are based upon assumptions about future economic conditions and courses of
action. All statements and information other than statements of historical fact
may be forward-looking statements. In some cases, forward-looking statements
can be identified by the use of words such as “seek”, “expect”, “anticipate”,
“budget”, “plan”, “estimate”, “continue”, “forecast”, “intend”, “believe”,
“predict”, “potential”, “target”, “may”, “could”, “would”, “might”, “will” and
similar words or phrases (including negative variations) suggesting future
outcomes or statements regarding an outlook.  Such forward-looking
statements are based on a number of material factors and assumptions and
involve known and unknown risks, uncertainties and other factors which may
cause actual results, performance or achievements, or industry results, to
differ materially from those anticipated in such forward-looking information.
You are cautioned not to place undue reliance on forward-looking statements
contained in this press release. Some of the known risks and other factors
which could cause actual results to differ materially from those expressed in
the forward-looking statements are described in the sections entitled “Risk
Factors” in Allegiant’s Listing Application, dated January 24, 2018, as filed
with the TSX Venture Exchange and available on SEDAR under Allegiant’s profile
at www.sedar.com. 
Actual results and future events could differ materially from those anticipated
in such statements. Allegiant undertakes no obligation to update or revise any
forward-looking statements included in this press release if these beliefs,
estimates and opinions or other circumstances should change, except as
otherwise required by applicable law.

Cannabis Industry Stimulating Economy to the Tune of $100 Billion

Posted on by Admin 


Image credit: RODNAE Productions


The Full Value of Marijuana on the U.S. Economy

 

Now that the Marijuana Opportunity Reinvestment and Expungement (MORE) Act has passed the House, the debate about the benefits of legalization will rage in the Senate before it votes. There’s no doubt the conversation will include reduced crime, reduced criminal justice costs, public health, and increased tax revenue while stimulating the economy. But, will their measure of economic stimulation and benefit be accurate?

Cannabis as an Economic Stimulant

As the economy has come into sharp focus as of late and impacts most Senator’s constituents, this may be the decider that changes the minds of those on the fence. Economic benefits may trump all others, allowing the bill to get the needed 60 votes, making the Oval Office the last hurdle toward legalization on a national level.

The economic benefit often focused on by state governments is that which is most easily measured, tax revenues. But as those in Washington know, a few extra jobs and a few extra dollars go a long way to stimulate economic growth. In this category, the cannabis industry has a lot to offer the country. Money changing hands for goods and services include the easy to recognize sales and the ancillary benefits of commerce beyond the doors of a dispensary.

Cannabis Industry’s Forecasted Benefit on U.S. Economy 2021-26


Data Source: MJBizfactbook

Marijuana Industry’s Impact (Beyond Sales)

Using data compiled by MJBizDaily, the total U.S. economic impact of marijuana sales that don’t include direct sales themselves, in 2022 is expected to rise 20% to reach $99 billion this year. And under the best estimates exceed $155 billion in 2026.

To measure and forecast the industry’s economic impact, the data team at MJBizDaily analyzed similar industries, consulted with economists, and then calculated and applied a standard multiplier of 2.8 on projected recreational and medical marijuana retail sales. The nature of a new and unique industry adds a greater element of unknown compared to forecasting other industries, but the methodology was well thought out and the measurements and factors created are as accurate as possible.

Beyond straight retail sales, which are also projected on the chart above, the industry includes farming, manufacturing, marketing, and hospitality. Marijuana production starts with agriculture at the farm. Economists use a multiplier of 1.9 on agricultural components. This equates to $11 billion for the U.S. economy, just in this category. To put it in a way that more visually shows the benefit, for every $10 consumers or patients spend at marijuana retail locations, an additional $18 will be injected into the economy.

That higher economic benefit comes from the day-to-day needs increased and then satisfied by workers in the cannabis industry, and then the further impact that includes spending on life’s necessities such as housing, transportation, entertainment, and more. Not very different than the massive impact that the stimulus checks had during the pandemic, money multiplies across the economy as it is spent and then put in someone else’s hands for their use.

Take-Away

Cannabis, as with other industries, has an impact on many other sectors that make its overall economic impact far greater than simply measuring the sales of cannabis. While the Senate and the President will consider many factors in deciding whether the MORE Act should become law, the overall positive economic impact should not be understated.

Paul Hoffman

Managing Editor, Channelchek

 

Suggested Reading



Marijuana Hits the House This Spring

Cannabis Bill Proposed by Republican House Member Softer on Marijuana Taxes





The Future of Cannabis Crosses Many Industries

Cannabis Customers Served by the Ice Cream Truck Delivery Model

 

Sources

https://thehill.com/news/house/3256370-house-approves-bill-legalizing-marijuana/

https://thehill.com/news/senate/3262866-democrats-face-tough-climb-on-winning-senate-approval-of-legal-marijuana/

https://www.cato.org/policy-analysis/effect-state-marijuana-legalizations-2021-update#history-state-level-marijuana-legalizations

https://mjbizdaily.com/wp-content/uploads/2022/04/2022-economic-impact-1.webp

https://mjbizdaily.com/marijuana-industry-will-add-nearly-100-billion-to-us-economy-in-2022/

 

Stay up to date. Follow us:

 

GABY (GABLF) Scheduled to Present at NobleCon18 Investor Conference

Posted on by Admin

GABY Founder & CEO Margot Micallef provides a preview of their upcoming presentation at NobleCon18

NobleCon18 – Noble Capital Markets 18th Annual Small and Microcap Investor Conference – April 19-21, 2022 – Hard Rock, Hollywood, FL 100+ Public Company Presentations | Scheduled Breakouts | Panel Presentations | High-Profile Keynotes | Educational Sessions | Receptions & Networking Events

Free Registration Available – More Info


Research News and Advanced Market Data on GABLF


NobleCon18 Presenting Companies

About GABY

GABY Inc. is a California-focused retail consolidator and the owner of Mankind Dispensary, one of the oldest licensed dispensaries in California. Mankind is a well-known, and highly respected dispensary with deep roots in the California cannabis community operating in San Diego, California. GABY curates and sells a diverse portfolio of products, including its own proprietary brands, Lulu’s™ and Kind Republic™ through Mankind, manufactures Kind Republic, and distributes all its proprietary brands through its wholly owned subsidiary, GABY Manufacturing. A pioneer in the industry with a multi-vertical retail foundation, and a strong management team with experience in retail, consolidation, and cannabis, GABY is poised to grow its retail operations both organically and through acquisition. GABY’s shares trade on the Canadian Securities Exchange (“CSE”) under the symbol “GABY” and on the OTCQB under the symbol “GABLF”. For more information on GABY, visit GABYInc.com.

Bowlero Corporation (BOWL) Scheduled to Present at NobleCon18 Investor Conference

Posted on by Admin

Bowlero provides a preview of their upcoming presentation at NobleCon18

NobleCon18 – Noble Capital Markets 18th Annual Small and Microcap Investor Conference – April 19-21, 2022 – Hard Rock, Hollywood, FL 100+ Public Company Presentations | Scheduled Breakouts | Panel Presentations | High-Profile Keynotes | Educational Sessions | Receptions & Networking Events

Free Registration Available – More Info


Research News and Advanced Market Data on BOWL


NobleCon18 Presenting Companies

About Bowlero

Bowlero Corp. is the worldwide leader in bowling entertainment. With more than 300 bowling centers across North America, Bowlero Corp. serves more than 26 million guests each year through a family of brands that includes Bowlero, Bowlmor Lanes, and AMF. Bowlero Corp. is also home to the Professional Bowlers Association, which it acquired in 2019 and which boasts thousands of members and millions of fans across the globe. For more information on Bowlero Corp., please visit BowleroCorp.com.

Lineage Cell Therapeutics (LCTX) Scheduled to Present at NobleCon18 Investor Conference

Posted on by Admin

Lineage Cell Therapeutics CEO Brian Culley provides a preview of their upcoming presentation at NobleCon18

NobleCon18 – Noble Capital Markets 18th Annual Small and Microcap Investor Conference – April 19-21, 2022 – Hard Rock, Hollywood, FL 100+ Public Company Presentations | Scheduled Breakouts | Panel Presentations | High-Profile Keynotes | Educational Sessions | Receptions & Networking Events

Free Registration Available – More Info


Research News and Advanced Market Data on LCTX


NobleCon18 Presenting Companies

About Lineage Cell Therapeutics

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include four allogeneic (“off-the-shelf”) product candidates: (i) OpRegen, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, which is now being developed under a worldwide collaboration with Roche and Genentech, a member of the Roche Group; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; (iii) VAC2, a dendritic cell therapy produced from Lineage’s VAC technology platform for immuno-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer and (iv) ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy. For more information, please visit www.lineagecell.com or follow the Company on Twitter @LineageCell.

BlackBoxStocks (BLBX) Scheduled to Present at NobleCon18 Investor Conference

Posted on by Admin

BlackBoxStocks provides a preview of their upcoming presentation at NobleCon18

NobleCon18 – Noble Capital Markets 18th Annual Small and Microcap Investor Conference – April 19-21, 2022 – Hard Rock, Hollywood, FL 100+ Public Company Presentations | Scheduled Breakouts | Panel Presentations | High-Profile Keynotes | Educational Sessions | Receptions & Networking Events

Free Registration Available – More Info


Research News and Advanced Market Data on BLBX


NobleCon18 Presenting Companies

About Blackboxstocks

Blackboxstocks, Inc. is a financial technology and social media hybrid platform offering real-time proprietary analytics and news for stock and options traders of all levels. Our web-based software employs “predictive technology” enhanced by artificial intelligence to find volatility and unusual market activity that may result in the rapid change in the price of a stock or option. Blackbox continuously scans the NASDAQ, New York Stock Exchange, CBOE, and all other options markets, analyzing over 10,000 stocks and up to 1,500,000 options contracts multiple times per second. We provide our users with a fully interactive social media platform that is integrated into our dashboard, enabling our users to exchange information and ideas quickly and efficiently through a common network. We recently introduced a live audio/video feature that allows our members to broadcast on their own channels to share trade strategies and market insight within the Blackbox community. Blackbox is a SaaS company with a growing base of users that spans 42 countries; current subscription fees are $99.97 per month or $959.00 annually. For more information, go to: www.blackboxstocks.com .

Lithium Inflation and Availability Concerns Elon Musk

Posted on by Admin 


Image credit: Steve Jurvetson (Flickr)


Elon Musk Does Not Want Lithium Production Levels to Stall the Growth of Tesla

 

Is the pace of lithium extraction going to continue to be a drag on EV manufacturing? Elon Musk, CEO of Tesla (TSLA), has no intention of allowing lithium costs or availability to depress his EV company’s growth. In one of his more serious tweets, Musk mentions the challenge of securing supply for Lithium-ion batteries and hints at a possible solution for the company he founded.

Musk was commenting on a Tweet from World of Statistics, which showed the price of lithium over the past ten years has risen from $4,450/tonne to $78,032/tonne today. Musk’s tweet offered a possible solution for Tesla to get ahead of the supply issue (a tonne, or metric Ton, is equal to 1000kg, about 2,205 pounds).

Musk’s Lithium Comment

In his tweet he mentions how “insane” the price of lithium has become. He also points out that the world has enough of the mineral, but extracting and refining hasn’t been able to keep up with growing needs. The CEO even suggested that Tesla might get into the mining business to help resolve shortages of the critical element used in li-ion batteries.

If Tesla also mined and refined needed raw materials to make sure production growth doesn’t stall, it would be unique in car company history. And, from an investor’s standpoint, it opens questions. We recently experienced how the chip shortage created havoc for car companies and buyers. One missing ingredient can prevent manufacturing at the ideal pace to meet consumer demand. Will locking up long-term lithium supply become standard? Will Tesla and other auto companies integrate supplying themselves with materials become part of who survives in the EV era and who doesn’t? What does this mean for li-ion-related stocks?

 

 

“Insane Levels”

Benchmark lithium prices are at about $78,000/tonne; this is an 80% increase from January 1st. Barrons tracks the price for a basket of lithium battery elements and has reported that it is up 60% on the year (April 2022). This increase adds on average another $2,000 to the price of an EV. Most materials to manufacture batteries (copper, cobalt, nickel, lithium) are secured on a contract basis. This helps smooth unexected changes allowing companies to better predict future costs.

Looking Forward

In a later tweet Musk wrote, “we have some cool ideas for sustainable lithium extraction [and] refinement.” Which will be worth watching. In the interim, lithium mining stocks are up 20-30% this year. Many are playing catch-up and and building their capacity to meet EV demand growth. The miners are behind the growth curve, but that isn’t because of a shortage of the mineral.

Paul Hoffman

Managing Editor, Channelchek

 

Suggested Reading



Lithium Prices Continue Their Ascent

Enough US Produced Lithium to Exceed Today’s Demand





Lithium-Ion Power vs Hydrogen Fuel Cell

Michael Burry Sees Positive in Elon Musk’s Twitter Stake

 

Sources

Twitter/ElonMusk/Lithium

https://www.barrons.com/articles/tesla-evs-inflation-metals-nickel-prices-51646744059?mod=article_inline

https://www.teslarati.com/tesla-lithium-mining/

 

Stay up to date. Follow us:

 

New Tool Reveals How Immune Cells Find their Targets

Posted on by Admin 


Image credit: S. Pincus, E. Fischer, Austin Athman (NIH)


Improved Method to Identify B or T cells that Interact with Viral or Bacterial Proteins

 

Anne Trafton | MIT News Office

The human body has millions of unique B and T cells that roam the body, looking for microbial invaders. These immune cells’ ability to recognize harmful microbes is critical to successfully fighting off infection.

MIT biological engineers have now devised an experimental tool that allows them to precisely pick out interactions between a particular immune cell and its target antigen. The new technique, which uses engineered viruses to present many different antigens to huge populations of immune cells, could allow large-scale screens of such interactions.

“This technique leads the way to understand immunity much closer to how the immune system itself actually works, will help researchers make sense of complex immune recognition in a variety of diseases, and could accelerate the development of more effective vaccines and immunotherapies,” says Michael Birnbaum, an associate professor of biological engineering at MIT, a member of MIT’s Koch Institute for Integrative Cancer Research, and the senior author of the study.

Former MIT graduate student Connor Dobson is the lead author of the paper, which appears in Nature Methods.

A Simple Screen for a Complex System

Both B and T cells play critical roles in launching an immune response. When a T cell encounters its target, it starts proliferating to produce an army of identical cells that can attack infected cells. And B cells that encounter their target begin producing antibodies that help recruit other components of the immune system to clear the infection.

Scientists who study the immune system have several tools to help them identify specific antigen-immune cell interactions. However, these tools generally only allow for the study of a large pool of antigens exposed to one B or T cell, or a large pool of immune cells encountering a small number of antigens.

“In your body, you have millions of unique T cells, and they could recognize billions of possible antigens. All of the tools that have been developed to this point are really designed to look at one side of that diversity at a time,” Birnbaum says.

The MIT team set out to design a new tool that would let them screen huge libraries of both antigens and immune cells at the same time, allowing them to pick out any specific interactions within the vast realm of possibilities.

To create a simple way to screen so many possible interactions, the researchers engineered a specialized form of a lentivirus, a type of virus that scientists often use to deliver genes because it can integrate pieces of DNA into host cells. These viruses have an envelope protein called VSV-G that can bind to receptors on the surface of many types of human cells, including immune cells, and infect them.

For this study, the researchers modified the VSV-G protein so that it cannot infect a cell on its own, instead relying on an antigen of the researchers’ choosing. This modified version of VSV-G can only help the lentivirus get into a cell if the paired antigen binds to a human B or T-cell receptor that recognizes the antigen.

Once the virus enters, it integrates itself into the host cell’s genome. Therefore, by sequencing the genome of all the cells in the sample, the researchers can discover both the antigen expressed by the virus that infected the cell and the sequence of the T or B-cell receptor that allowed it to enter.

“In this way, we can use viral infection itself as a way to match up and then identify antigen-immune cell parings,” Birnbaum says.

Interactions Identified

To demonstrate the accuracy of their technique, the researchers created a pool of viruses with antigens from 100 different viruses, including influenza, cytomegalovirus, and Epstein-Barr virus. They screened these viruses against about 400,000 T cells and showed that the technique could correctly pick out antigen-T-cell receptor pairings that had been previously identified.

The researchers also screened two different B-cell receptors against 43 antigens, including antigens from HIV and the spike protein of SARS-CoV-2.

In future studies, Birnbaum hopes to screen thousands of antigens against B and T cell populations. “Our ideal would be to screen entire viruses or families of viruses, to be able to get a readout of your entire immune system in one experiment,” he says.

In one study that is now ongoing, Birnbaum’s lab is working with researchers at the Ragon Institute of MGH, MIT, and Harvard to study how different people’s immune systems respond to viruses such as HIV and SARS-CoV-2. Such studies could help to reveal why some people naturally fight off certain viruses better than others, and potentially lead to the development of more effective vaccines.

The researchers envision that this technology could also have other uses. Birnbaum’s lab is now working on adapting the same viruses to deliver engineered genes to target cells. In that case, the viruses would carry not only a targeting molecule but also a novel gene that would be incorporated exclusively into cells that have the right target. This could offer a way to selectively deliver genes that promote cell death into cancer cells, for example.

“We built this tool to look for antigens, but there’s nothing particularly special about antigens,” Birnbaum says. “You could potentially use it to go into specific cells in order to do gene modifications for cell and gene therapy.”

 

Suggested Reading



Stem-Cell Based Therapy for Alzheimer’s Disease

Stem Cells Role in the Anti-Aging Business





Stem Cell-Derived Retinal Pigment Epithelium Cells – Vision for the Future

The Appeal of EVs with Bidirectional Charging

 

Stay up to date. Follow us:

 

Release – Lineage to Present at the NobleCon18 Investor Conference on April 20, 2022

Posted on by Admin

 


Lineage to Present at the NobleCon18 Investor Conference on April 20, 2022

Research, News, and Market Data on Lineage Cell Therapeutics

CARLSBAD, Calif.–(BUSINESS WIRE)–Apr. 11, 2022–

Lineage Cell Therapeutics, Inc.

 (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, the Company’s Chief Executive Officer, will be presenting at NobleCon18 – Noble Capital Markets’ Eighteenth Annual Investor Conference on
April 20th, 2022 at
4:30pm ET
in Seminole Ballroom A. NobleCon18 is taking place at the
Hard Rock Hotel & Casino in
Hollywood, Florida
,
April 19th – 21st, 2022.

An archived webcast of the corporate presentation will be available starting
April 21st, 2022 on the Events and Presentations page of the Lineage website, and as part of a complete catalog of presentations available on the conference website: www.nobleconference.com and on Channelchek www.channelchek.com, the investor portal created by
Noble Capital Markets. Additional videos are available on the Media page of the Lineage website.

About Lineage
Cell Therapeutics, Inc.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include four allogeneic (“off-the-shelf”) product candidates: (i) OpRegen, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, which is now being developed under a worldwide collaboration with Roche and
Genentech, a member of the Roche Group; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; (iii) VAC2, a dendritic cell therapy produced from Lineage’s VAC technology platform for immuno-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer and (iv) ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy. For more information, please visit www.lineagecell.com or follow the Company on Twitter @LineageCell.

Lineage Cell Therapeutics, Inc. IR Ioana C. Hone (
ir@lineagecell.com)
(442) 287-8963

Solebury
Trout IR Mike Biega (
Mbiega@soleburytrout.com)

(617) 221-9660

Russo
Partners – Media Relations Nic Johnson or David Schull Nic.johnson@russopartnersllc.com

David.schull@russopartnersllc.com

(212) 845-4242

Source:
Lineage Cell Therapeutics, Inc.

Release – Endeavour Silver Delivers Strong Production in Q1 2022

Posted on by Admin



Endeavour Silver Delivers Strong Production in Q1 2022

Research, News, and Market Data on Endeavour Silver

VANCOUVER, British
Columbia, April 11, 2022 (GLOBE NEWSWIRE) — Endeavour Silver Corp.
(“Endeavour” or the “Company”) (NYSE: EXK; TSX: EDR) is pleased to report first quarter 2022 production of 1,314,955 silver ounces (oz) and 8,695 gold oz, for silver equivalent 1 (“AgEq”) production of 2.0 million oz.

“The year is off to a strong start,” stated Dan Dickson, Chief Executive Officer. “Operationally, Guanacevi continues to outperform production expectations and Bolañitos remains steady. Strategically, we made a significant move in January signing a definitive agreement to acquire the Pitarrilla Project, one of the world’s largest undeveloped silver deposits. The addition of Pitarrilla, which is expected to close in the second quarter, significantly enhances our already attractive pipeline of growth projects, which also includes Terronera and Parral.”

Q1 2022
Highlights

  • Guanacevi
    Continued to Outperform:     Silver and gold production exceeded plan driven by higher grades.
  • Bolañitos’
    Performance Remained Steady:     Strong silver production, higher silver grades and increased throughput were offset by the impact of lower than anticipated gold production and lower gold grades.
  • Metal
    Sales and Inventories     : Sold 1,717,768 oz silver and 8,381 oz gold during the quarter. Held 608,788 oz silver and 1,911 oz gold of bullion inventory and 59,594 oz silver and 1,931 oz gold in concentrate inventory at quarter end.
  • Advancing
    the Terronera Project     : Work continued on final detailed engineering, early earth works, critical contracts and the procurement of long lead items.   The Company intends to make a formal construction decision subject to completion of a financing package and receipt of additional amended permits in the coming months.
  • Announced
    Definitive Agreement to Acquire the Pitarrilla Project:     Endeavour is acquiring Pitarrilla, one of the largest undeveloped silver deposits in the world, from SSR Mining Inc. in a transaction expected to close in Q2 2022. Pitarrilla is located in Durango State, Mexico, which has a long history of mining and is known as a mining-friendly jurisdiction with several mines in operation, including our Guanacevi mine.
  • Completed
    US$46.0 Million Bought Deal Financing:     On March 22, 2022 Endeavour completed a prospectus offering for the issuance of 9,293,150 common shares at a price of US$4.95 per common share for gross proceeds of US$46.0 million, including the exercise of an over-allotment option. The Company plans to use the net proceeds to pay the US$35 million cash consideration payable to SSR Mining Inc. on completion of the Company’s acquisition of the Pitarrilla project and for the Company’s general corporate purposes and working capital.

Q1 2022 Mine
Operations

Consolidated silver production increased by 25% to 1,314,955 ounces in Q1 2022 compared to Q1 2021, primarily driven by a 23% increase in silver production at the Guanacevi mine and a 70% increase in silver production at the Bolañitos mine offset by nil production at El Compas, which the Company put on care and maintenance last August.

Gold production decreased by 22% to 8,695 ounces as a 27% increase in gold production at the Guanacevi mine was offset by a 16% decrease in gold production at the Bolañitos mine and nil production at El Compas.

Guanacevi throughput in Q1 2022 was 14% higher than Q1 2021 and silver grades and gold grades were 10% and 13% higher, respectively. Guanacevi throughput met plan and mining the new higher grade El Curso orebody has led to significantly improved grades and mine flexibility. Additionally, supplies of local third-party ores continued to supplement mine production, amounting to 11% of quarterly throughput and contributing to the higher ore grades.

Bolañitos Q1 2022 throughput was 7% higher than Q1 2021 with silver grades 61% higher and gold grades 20% lower. Silver production increased by 70% while gold production decreased by 16% at the Bolañitos mine.

Production
Highlights for the Three Months Ended March 31, 2022

Q1
2022 Highlights

Three Months Ended March 31,

 

2022

2021

% Change

Throughput (tonnes)

206,147

209,453

(2%)

Silver ounces produced

1,314,955

1,048,100

25%

Gold ounces produced

8,695

11,109

(22%)

Payable silver ounces produced

1,303,540

1,036,710

26%

Payable gold ounces produced

8,549

10,894

(22%)

Silver equivalent ounces produced 1

2,010,555

1,936,820

4%

Silver ounces sold

1,717,768

623,379

176%

Gold ounces sold

8,381

10,663

(21%)

Q1 2022
Production by Mine

Production

Tonnes

Tonnes

Grade

Grade

Recovery

Recovery

Silver

Gold

by
mine

Produced

per day

Ag gpt*

Au gpt*

Ag %

Au %

Oz

Oz

Guanaceví

101,253

1,125

407

1.19

85.6%

89.8%

1,133,850

3,477

Bolañitos

104,894

1,165

61

1.73

88.0%

89.4%

181,105

5,218

Consolidated

206,147

2,291

231

1.46

85.9%

89.6%

1,314,955

8,695

*gpt = grams per
tonne

Q1 2022 Financial
Results and Conference Call

The Company’s Q1 2022 financial results will be released before markets open on Wednesday, May 11, 2022 and a telephone conference call will be held the same day at 10:00 a.m. PT / 1:00 p.m. ET. To participate in the conference call, please dial the numbers below.

Date & Time:

Wednesday, May 11, 2022 at 10:00 a.m. PT / 1:00 p.m. ET

 

 

Telephone:

Toll-free in Canada and the US +1-800-319-4610

 

Local or International +1-604-638-5340

 

Please allow up to 10 minutes to be connected to the conference call.

 

 

Replay:

A replay of the conference call will be available by dialing (toll-free) +1-800-319-6413 in Canada and the US (toll-free) or +1-604-638-9010 outside of Canada and the US. The replay passcode is 8312#. The replay will also be available on the Company’s website at www.edrsilver.com
.

About Endeavour
Silver – Endeavour Silver Corp. is a mid-tier precious metals mining company that operates two high-grade underground silver-gold mines in Mexico. Endeavour is currently advancing the Terronera mine project towards a development decision, pending financing and final permits and exploring its portfolio of exploration and development projects in Mexico, Chile and the United States to facilitate its goal to become a premier senior silver producer.  Our philosophy of corporate social integrity creates value for all stakeholders.

SOURCE Endeavour Silver Corp.

Contact
Information
Trish Moran
Interim Head of Investor Relations
Tel: (416) 564-4290
Email: pmoran@edrsilver.com
Website: www.edrsilver.com

Follow Endeavour Silver on Facebook ,
Twitter ,
Instagram and
LinkedIn

Cautionary Note
Regarding Forward-Looking Statements

This news release
contains “forward-looking statements” within the meaning of the United States
private securities litigation reform act of 1995 and “forward-looking
information” within the meaning of applicable Canadian securities legislation.
Such forward-looking statements and information herein include but are not
limited to statements regarding Endeavour’s anticipated performance in 2022
including changes in mining operations and production levels, the timing and
results of various activities and the impact of the COVID 19 pandemic on
operations. The Company does not intend to and does not assume any obligation
to update such forward-looking statements or information, other than as
required by applicable law.

Forward-looking
statements or information involve known and unknown risks, uncertainties and
other factors that may cause the actual results, level of activity, production
levels, performance or achievements of Endeavour and its operations to be
materially different from those expressed or implied by such statements. Such
factors include but are not limited to the ultimate impact of the COVID 19
pandemic on operations and results, changes in production and costs guidance,
national and local governments, legislation, taxation, controls, regulations
and political or economic developments in Canada and Mexico; financial risks
due to precious metals prices, operating or technical difficulties in mineral exploration,
development and mining activities; risks and hazards of mineral exploration,
development and mining; the speculative nature of mineral exploration and
development, risks in obtaining necessary licenses and permits, and challenges
to the Company’s title to properties; as well as those factors described in the
section “risk factors” contained in the Company’s most recent form 40F/Annual
Information Form filed with the S.E.C. and Canadian securities regulatory
authorities.

Forward-looking
statements are based on assumptions management believes to be reasonable,
including but not limited to: the continued operation of the Company’s mining
operations, no material adverse change in the market price of commodities,
mining operations will operate and the mining products will be completed in
accordance with management’s expectations and achieve their stated production
outcomes, and such other assumptions and factors as set out herein. Although
the Company has attempted to identify important factors that could cause actual
results to differ materially from those contained in forward-looking statements
or information, there may be other factors that cause results to be materially
different from those anticipated, described, estimated, assessed or intended. There
can be no assurance that any forward-looking statements or information will
prove to be accurate as actual results and future events could differ
materially from those anticipated in such statements or information.
Accordingly, readers should not place undue reliance on forward-looking
statements or information.

_____________________________________________
1 Silver equivalent calculated using an 80:1 silver:gold ratio.

Release – Comtech Welcomes Robert Samuels as Vice President of Investor Relations and Corporate Communications

Posted on by Admin



Comtech Welcomes Robert Samuels as Vice President of Investor Relations and Corporate Communications

Research, News, and Market Data on Comtech Telecommunications

Samuels Takes IR Helm as Comtech Scales into Growing Failsafe
Communications Market Opportunities

MELVILLE, N.Y.
–(BUSINESS WIRE)–Apr. 11, 2022– 
April 11, 2022— 
Comtech Telecommunications Corp. (NASDAQ: CMTL), a leading global provider of next-generation 911 emergency systems and secure wireless communications technologies, today announced that it has named investment and financial analysis expert  Robert Samuels as its Vice President of Investor Relations and Corporate Communications. This newly created position will significantly enhance Comtech’s commitment to shareholder engagement and transparency.

Samuels brings over 20 years of 
Wall Street
 experience from working at leading financial institutions, including UBS Global Wealth Management, where he served in the Chief Investment Office, producing company-specific and thematic research, as well as marketing collateral for the firm’s financial advisors and private clients. While at 
UBS, Samuels drove investment performance of tens of billions worth of assets, outperforming the sector benchmark and S&P 500 for five consecutive years.

“As we turn 
Comtech into becoming the most trusted provider of 
Failsafe Communications
, we want to increase engagement around our transformation with the entire financial community,” said  Michael Porcelain , President and CEO of 
Comtech. “Having a seasoned investment professional like Robert on our team strengthens our ability to tell Comtech’s compelling story and elevate our brand. Robert will assist Comtech’s leadership in its ongoing evaluation of potential new segment reporting and non-GAAP financial measures, and the roll out of our new social media initiatives. I am confident that with his expertise and fresh insights, Robert will make a strong contribution to Comtech.”

“I’ve focused my work on industries that impact people in their daily lives,” said  Robert Samuels. “What Comtech does is undeniably critical, as it provides 
Failsafe Communications
 that people, businesses, and governments know they can rely on, no matter where they are – on land, at sea, or in the air – and no matter what’s going on outside – from armed conflict to a natural disaster. I look forward to amplifying that exciting story and helping to convey the strong investment opportunity it represents.”

About Comtech

Comtech Telecommunications Corp. is a leading global provider of next-generation 911 emergency systems and secure wireless communications technologies to commercial and government customers around the world. Headquartered in 
Melville, New York and with a passion for customer success, 
Comtech designs, produces and markets advanced and secure wireless solutions. For more information, please visit www.comtechtel.com (and preview its new website at www.comtech.com).

Certain information in this press release contains statements that are forward-looking in nature and involve certain significant risks and uncertainties. Actual results could differ materially from such forward-looking information. The Company’s 
Securities and Exchange Commission filings identify many such risks and uncertainties. Any forward-looking information in this press release is qualified in its entirety by the risks and uncertainties described in such 
Securities and Exchange Commission filings.

PCMTL

Investor Relations Robert Samuels 631-962-7102
robert.samuels@comtech.com

Source: 
Comtech Telecommunications Corp.

Tokens.com (SMURF) – Is This the Real Life or is it Fantasy?

Posted on by Admin

Monday, April 11, 2022

Tokens.com (SMURF)
Is This the Real Life or is it Fantasy?

Tokens.com Corp is a Proof-of-Stake technology company that provides investors with a secure way to gain exposure to staking rewards and cryptocurrencies. It provides investors with exposure to the digital assets that power Decentralized Finance and Non-Fungible Tokens, without the burden of buying, managing, and securing digital assets themselves. The company creates value for its investors through earning Staking yields and the appreciation of its digital asset inventory, all achieved through environmentally friendly technology.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Taking Up More Space.  Tokens.com’s management recently announced the acquisition of 40 plots of virtual land from SuperWorld. In this acquisition, Metaverse Group acquired landmark locations such as the Central Park Zoo, the Eden Fine Art Gallery in Manhattan, the Pelican Hotel in Miami Beach, and the Louis Vuitton store in Las Vegas.

    What is SuperWorld?  SuperWorld is a virtual world that has digitally mapped Planet Earth and plotted the land to be sold as non-fungible token (NFT) virtual real estate. Each plot of land corresponds to a physical world space, and includes landmarks such as…

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

 

Schwazze (SHWZ) – Post Call Commentary and Updated Model

Posted on by Admin

Monday, April 11, 2022

Schwazze (SHWZ)
Post Call Commentary and Updated Model

Medicine Man Technologies, Inc. is now operating under its new trade name, Schwazze. Schwazze is executing its strategy to become a leading vertically integrated cannabis holding company with a portfolio consisting of top-tier licensed brands spanning cultivation, extraction, infused-product manufacturing, dispensary operations, consulting, and a nutrient line. Schwazze leadership includes Colorado cannabis leaders with proven expertise in product and business development as well as top-tier executives from Fortune 500 companies. As a leading platform for vertical integration, Schwazze is strengthening the operational efficiency of the cannabis industry in Colorado and beyond, promoting sustainable growth and increased access to capital, while delivering best-quality service and products to the end consumer. The corporate entity continues to be named Medicine Man Technologies, Inc.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Post Management Call. We had an opportunity to speak with Schwazze CEO Justin Dye and CFO Nancy Huber following the release of fourth quarter earnings. Our discussion revolved around the Colorado and New Mexico operations, what’s next for those operations, and where the Company can go from here, including potential additional expansion.

    Implementing the Playbook.  All but one of the announced acquisitions has now been closed. We view 2022 as a year of integrating the acquisitions and implementing the Schwazze operating playbook to drive revenue and margins. While the cannabis market will see ebbs and flows, we expect Schwazze to…

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.